Aesthera Corp. has announced the U.S. Food and Drug Administration’s clearance of its Aesthera Photopneumatic (PPx)™ System for the treatment of vascular and pigmented lesions and permanent hair reduction. The company touts its product as “the first no pain and safer light based therapy to treat sun damaged and aging skin, including brown spots, redness and broken capillaries, as well as unwanted hair and unsightly veins.”
This is how the PPx technology works, according to the company:
Photopneumatic Technology is a breakthrough proprietary technology that innovatively combines the unique properties of broadband light with pneumatic energy to deliver 4-5x more efficient photons to dermal and epidermal targets. As a result of a unique proprietary mechanism, 4-5 times less energy is required for effective treatments. Aesthera PPx treatments are consequently painless and up to 4 times safer than other traditional light based treatments.
Using a proprietary pneumatic sequence, the treatment area is stretched to reduce the concentration of absorptive chromophores of blood and melanin.
When light is applied to the skin, elevated targets, reduced melanin and blanched dermal vessels allow 4x – 5x more photons to impact the target. As a result of its highly efficient delivery, Photopneumatic therapy produces excellent clinical outcomes with no pain, extreme safety and no thermal compromise to surrounding normal tissue.
More at Aesthera…